lebrikizumab vs REGN20423

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Atopic Dermatitis

Shared mechanism: IL-13 · full Atopic Dermatitis pipeline

lebrikizumab · Ebglyss

Marketed by Eli Lilly and partners

Approved in Atopic Dermatitismonoclonal antibody
Reliable signal

NCT04146363 · Phase 3 · completed

The randomized, quadruple-masked, placebo-controlled trial enrolled 424 participants and evaluated clinical skin outcomes as its two primary endpoints. At Week 16, both endpoints were met: IGA 0/1 response was 43.1% with lebrikizumab versus 12.7% with placebo (p<0.000001), and EASI-75 response was 58.8% versus 16.2% (p<0.000001).

Next expected readout: April 2027 · NCT06526182 (registry estimate)

Reported efficacy

Percentage of Participants With an Investigator Global Assessment (IGA) Score of 0 or 1 and a Reduction ≥2 Points From Baseline to Week 16; Percentage of Participants Achieving Eczema Area And Severity Index (EASI-75) (≥75% Reduction in EASI Score) From Baseline to Week 16: Percentage of Participants With an Investigator Global Assessment (IGA) Score of 0 or 1 and a Reduction ≥2 Points From Baseline to Week 16 (Baseline to Week 16): Lebrikizumab Q2W 33.2% (95% CI 27.5 to 38.9) vs Placebo 10.8% (95% CI 5.7 to 15.9) (met)

Result source: NCT04178967

REGN20423

Developed by Regeneron Pharmaceuticals and partners

Phase 1 in Atopic Dermatitismonoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: August 2028 · NCT07527923 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Atopic Dermatitis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointlebrikizumabREGN20423
EASI-7551.2% vs 13.4%+37.8 vs placebo250 mg Q2W · wk 16 · n 123NCT04760314
10 other results
  • 58.8% vs 16.2% Q2W · wk 16 · n 283 · Phase 3 · primary NCT04146363
  • 52.1% vs 18.1% Q2W · wk 16 · n 281 · Phase 3 · primary NCT04178967
  • 47.2% vs 13.4% 250 mg Q4W · wk 16 · n 81 · Phase 3 · primary NCT04760314
  • 69.5% vs 42.2% wk 16 · n 145 · Phase 3 · primary NCT04250337
  • 58% vs 32.7% 250 mg · wk 16 · n 125 · Phase 3 · secondary NCT04626297
  • 84.7% vs 72% 250 Q4W · wk 52 · n 53 · Phase 3 · secondary NCT04178967
  • 77.4% vs 72% 250 Q2W · wk 52 · n 51 · Phase 3 · secondary NCT04178967
  • 60.6% vs 24.3% 250 mg Q2W · wk 16 · n 75 · Phase 2 · secondary NCT03443024
  • 56.1% vs 24.3% 250 mg Q4W · wk 16 · n 80 · Phase 2 · secondary NCT03443024
  • 43.3% vs 24.3% 125 mg Q4W · wk 16 · n 73 · Phase 2 · secondary NCT03443024
—Not reported
IGA 0/1 with 2-point improvement33.4% vs 6.1%+27.3 vs placebo250 mg Q2W · wk 16 · n 123NCT04760314
5 other results
  • 29.1% vs 6.1% 250 mg Q4W · wk 16 · n 81 · Phase 3 · primary NCT04760314
  • 41.2% vs 22.1% wk 16 · n 145 · Phase 3 · primary NCT04250337
  • 44.6% vs 15.3% 250 mg Q2W · wk 16 · n 75 · Phase 2 · secondary NCT03443024
  • 33.7% vs 15.3% 250 mg Q4W · wk 16 · n 80 · Phase 2 · secondary NCT03443024
  • 26.6% vs 15.3% 125 mg Q4W · wk 16 · n 73 · Phase 2 · secondary NCT03443024
—Not reported
EASI-9034.3% vs 9.8%+24.5 vs placebo250 mg Q2W · wk 16 · n 123NCT04760314
11 other results
  • 39.2% vs 18.9% 250 mg · wk 16 · n 125 · Phase 3 · secondary NCT04626297
  • 38.3% vs 9% Q2W · wk 16 · n 283 · Phase 3 · secondary NCT04146363
  • 30.7% vs 9.5% Q2W · wk 16 · n 281 · Phase 3 · secondary NCT04178967
  • 41.2% vs 21.7% wk 16 · n 145 · Phase 3 · secondary NCT04250337
  • 12.4% vs 1.6% Q2W · wk 4 · n 283 · Phase 3 · secondary NCT04146363
  • 6.3% vs 1.5% Q2W · wk 4 · n 281 · Phase 3 · secondary NCT04178967
  • 28.4% vs 9.8% 250 mg Q4W · wk 16 · n 81 · Phase 3 · secondary NCT04760314
  • 10.7% vs 7.2% wk 4 · n 145 · Phase 3 · secondary NCT04250337
  • 44% vs 11.4% 250 mg Q2W · wk 16 · n 75 · Phase 2 · secondary NCT03443024
  • 36.1% vs 11.4% 250 mg Q4W · wk 16 · n 80 · Phase 2 · secondary NCT03443024
  • 26.1% vs 11.4% 125 mg Q4W · wk 16 · n 73 · Phase 2 · secondary NCT03443024
—Not reported
EASI, % change-64.2% vs -25.3%−39 vs placebo250 mg Q2W · wk 16 · n 123NCT04760314
7 other results
  • -64.3% vs -26.0% Q2W · wk 16 · n 283 · Phase 3 · secondary NCT04146363
  • -61.5% vs -28.0% Q2W · wk 16 · n 281 · Phase 3 · secondary NCT04178967
  • -59.7% vs -25.3% 250 mg Q4W · wk 16 · n 81 · Phase 3 · secondary NCT04760314
  • -76.8% vs -53.1% wk 16 · n 145 · Phase 3 · secondary NCT04250337
  • -72.1% vs -41.1% 250 mg Q2W · wk 16 · n 75 · Phase 2 · primary NCT03443024
  • -69.2% vs -41.1% 250 mg Q4W · wk 16 · n 80 · Phase 2 · primary NCT03443024
  • -62.3% vs -41.1% 125 mg Q4W · wk 16 · n 73 · Phase 2 · primary NCT03443024
—Not reported

EASI-75

lebrikizumab
51.2% vs 13.4%+37.8 vs placebo250 mg Q2W · wk 16 · n 123NCT04760314
10 other results
  • 58.8% vs 16.2% Q2W · wk 16 · n 283 · Phase 3 · primary NCT04146363
  • 52.1% vs 18.1% Q2W · wk 16 · n 281 · Phase 3 · primary NCT04178967
  • 47.2% vs 13.4% 250 mg Q4W · wk 16 · n 81 · Phase 3 · primary NCT04760314
  • 69.5% vs 42.2% wk 16 · n 145 · Phase 3 · primary NCT04250337
  • 58% vs 32.7% 250 mg · wk 16 · n 125 · Phase 3 · secondary NCT04626297
  • 84.7% vs 72% 250 Q4W · wk 52 · n 53 · Phase 3 · secondary NCT04178967
  • 77.4% vs 72% 250 Q2W · wk 52 · n 51 · Phase 3 · secondary NCT04178967
  • 60.6% vs 24.3% 250 mg Q2W · wk 16 · n 75 · Phase 2 · secondary NCT03443024
  • 56.1% vs 24.3% 250 mg Q4W · wk 16 · n 80 · Phase 2 · secondary NCT03443024
  • 43.3% vs 24.3% 125 mg Q4W · wk 16 · n 73 · Phase 2 · secondary NCT03443024
REGN20423
—Not reported

IGA 0/1 with 2-point improvement

lebrikizumab
33.4% vs 6.1%+27.3 vs placebo250 mg Q2W · wk 16 · n 123NCT04760314
5 other results
  • 29.1% vs 6.1% 250 mg Q4W · wk 16 · n 81 · Phase 3 · primary NCT04760314
  • 41.2% vs 22.1% wk 16 · n 145 · Phase 3 · primary NCT04250337
  • 44.6% vs 15.3% 250 mg Q2W · wk 16 · n 75 · Phase 2 · secondary NCT03443024
  • 33.7% vs 15.3% 250 mg Q4W · wk 16 · n 80 · Phase 2 · secondary NCT03443024
  • 26.6% vs 15.3% 125 mg Q4W · wk 16 · n 73 · Phase 2 · secondary NCT03443024
REGN20423
—Not reported

EASI-90

lebrikizumab
34.3% vs 9.8%+24.5 vs placebo250 mg Q2W · wk 16 · n 123NCT04760314
11 other results
  • 39.2% vs 18.9% 250 mg · wk 16 · n 125 · Phase 3 · secondary NCT04626297
  • 38.3% vs 9% Q2W · wk 16 · n 283 · Phase 3 · secondary NCT04146363
  • 30.7% vs 9.5% Q2W · wk 16 · n 281 · Phase 3 · secondary NCT04178967
  • 41.2% vs 21.7% wk 16 · n 145 · Phase 3 · secondary NCT04250337
  • 12.4% vs 1.6% Q2W · wk 4 · n 283 · Phase 3 · secondary NCT04146363
  • 6.3% vs 1.5% Q2W · wk 4 · n 281 · Phase 3 · secondary NCT04178967
  • 28.4% vs 9.8% 250 mg Q4W · wk 16 · n 81 · Phase 3 · secondary NCT04760314
  • 10.7% vs 7.2% wk 4 · n 145 · Phase 3 · secondary NCT04250337
  • 44% vs 11.4% 250 mg Q2W · wk 16 · n 75 · Phase 2 · secondary NCT03443024
  • 36.1% vs 11.4% 250 mg Q4W · wk 16 · n 80 · Phase 2 · secondary NCT03443024
  • 26.1% vs 11.4% 125 mg Q4W · wk 16 · n 73 · Phase 2 · secondary NCT03443024
REGN20423
—Not reported

EASI, % change

lebrikizumab
-64.2% vs -25.3%−39 vs placebo250 mg Q2W · wk 16 · n 123NCT04760314
7 other results
  • -64.3% vs -26.0% Q2W · wk 16 · n 283 · Phase 3 · secondary NCT04146363
  • -61.5% vs -28.0% Q2W · wk 16 · n 281 · Phase 3 · secondary NCT04178967
  • -59.7% vs -25.3% 250 mg Q4W · wk 16 · n 81 · Phase 3 · secondary NCT04760314
  • -76.8% vs -53.1% wk 16 · n 145 · Phase 3 · secondary NCT04250337
  • -72.1% vs -41.1% 250 mg Q2W · wk 16 · n 75 · Phase 2 · primary NCT03443024
  • -69.2% vs -41.1% 250 mg Q4W · wk 16 · n 80 · Phase 2 · primary NCT03443024
  • -62.3% vs -41.1% 125 mg Q4W · wk 16 · n 73 · Phase 2 · primary NCT03443024
REGN20423
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

REGN20423: no structured comparison results are available for Atopic Dermatitis.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. lebrikizumab: 4 of 4 rows · REGN20423: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metriclebrikizumab
Dropout rate
—250mg Q2Wa
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 54 more results
—Q2W
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—Q2W
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—Escape Arm Week 24 to 48 - Mainten
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—Q2W
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—Q4W
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—Q2W
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—Q4W
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—250 Q2W
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—250 Q4W
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—250mg Q2W
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—Q2W
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—Q2W
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—Escape Arm Week 24 to 48 - Mainten
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—Q2W
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—Q4W
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—Q2W
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—Q4W
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—250 Q2W
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—250 Q4W
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
7.2%
NCT04250337 · Phase 3 · combination
6.5%
NCT05990725 · Phase 3 · registry result, not featured evidence
—Q4W
NCT04392154 · Phase 3 · registry result, not featured evidence
—Q8W
NCT04392154 · Phase 3 · registry result, not featured evidence
33.3%Q2W
NCT04392154 · Phase 3 · registry result, not featured evidence
27%Q4W
NCT04392154 · Phase 3 · registry result, not featured evidence
14.4%250 mg Q2W
NCT05372419 · Phase 3 · registry result, not featured evidence
—250 mg Q2W
NCT05372419 · Phase 3 · registry result, not featured evidence
—250 mg Q2W then 250 mg Q4W
NCT05372419 · Phase 3 · registry result, not featured evidence
—250 mg Q2W
NCT05372419 · Phase 3 · registry result, not featured evidence
—250 mg Q2W then 250 mg Q4W
NCT05372419 · Phase 3 · registry result, not featured evidence
31.4%250 mg Q2W
NCT05369403 · Phase 3 · registry result, not featured evidence
—250 mg Q2W
NCT05369403 · Phase 3 · registry result, not featured evidence
—250 mg Q2W then 250 mg Q4W
NCT05369403 · Phase 3 · registry result, not featured evidence
—250 mg Q2W
NCT05369403 · Phase 3 · registry result, not featured evidence
—250 mg Q2W then Q4W
NCT05369403 · Phase 3 · registry result, not featured evidence
0%Lebrikizumab Pen
NCT06444165 · Phase 3 · registry result, not featured evidence
—Lebrikuzimab Pen
NCT06444165 · Phase 3 · registry result, not featured evidence
3.6%Double-blind Induction Period: Leb
NCT05149313 · Phase 3 · registry result, not featured evidence · combination
—Open-label Maintenance Period: Leb
NCT05149313 · Phase 3 · registry result, not featured evidence
—250 mg Q2W
NCT04760314 · Phase 3 · registry result, not featured evidence
—250mg Q2W
NCT04760314 · Phase 3 · registry result, not featured evidence
—250mg Q2W
NCT04760314 · Phase 3 · registry result, not featured evidence
2.4%250mg Q2W
NCT04760314 · Phase 3 · registry result, not featured evidence
1.2%250mg Q4W
NCT04760314 · Phase 3 · registry result, not featured evidence
—250 Q2W
NCT04760314 · Phase 3 · registry result, not featured evidence
—Q4W
NCT04760314 · Phase 3 · registry result, not featured evidence
—Q2W
NCT04760314 · Phase 3 · registry result, not featured evidence
—Q4W
NCT04760314 · Phase 3 · registry result, not featured evidence
11%250 mg
NCT04626297 · Phase 3 · registry result, not featured evidence
16.5%250 mg
NCT04250350 · Phase 3 · registry result, not featured evidence
—250 mg
NCT04250350 · Phase 3 · registry result, not featured evidence
—250 mg Q2W
NCT03443024 · Phase 2 · registry result, not featured evidence
38.8%250 mg Q4W
NCT03443024 · Phase 2 · registry result, not featured evidence
—125 mg Q4W
NCT03443024 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
—250mg Q2Wa
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 54 more results
—Q2W
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—Q2W
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—Escape Arm Week 24 to 48 - Mainten
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—Q2W
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—Q4W
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—Q2W
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—Q4W
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—250 Q2W
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—250 Q4W
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—250mg Q2W
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—Q2W
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—Q2W
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—Escape Arm Week 24 to 48 - Mainten
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—Q2W
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—Q4W
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—Q2W
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—Q4W
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—250 Q2W
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—250 Q4W
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
2%
NCT04250337 · Phase 3 · combination
1.9%
NCT05990725 · Phase 3 · registry result, not featured evidence
—Q4W
NCT04392154 · Phase 3 · registry result, not featured evidence
—Q8W
NCT04392154 · Phase 3 · registry result, not featured evidence
4.5%Q2W
NCT04392154 · Phase 3 · registry result, not featured evidence
2.1%Q4W
NCT04392154 · Phase 3 · registry result, not featured evidence
—250 mg Q2W
NCT05372419 · Phase 3 · registry result, not featured evidence
—250 mg Q2W
NCT05372419 · Phase 3 · registry result, not featured evidence
—250 mg Q2W then 250 mg Q4W
NCT05372419 · Phase 3 · registry result, not featured evidence
—250 mg Q2W
NCT05372419 · Phase 3 · registry result, not featured evidence
—250 mg Q2W then 250 mg Q4W
NCT05372419 · Phase 3 · registry result, not featured evidence
5.8%250 mg Q2W
NCT05369403 · Phase 3 · registry result, not featured evidence
—250 mg Q2W
NCT05369403 · Phase 3 · registry result, not featured evidence
—250 mg Q2W then 250 mg Q4W
NCT05369403 · Phase 3 · registry result, not featured evidence
—250 mg Q2W
NCT05369403 · Phase 3 · registry result, not featured evidence
—250 mg Q2W then Q4W
NCT05369403 · Phase 3 · registry result, not featured evidence
—Lebrikizumab Pen
NCT06444165 · Phase 3 · registry result, not featured evidence
—Lebrikuzimab Pen
NCT06444165 · Phase 3 · registry result, not featured evidence
0.9%Double-blind Induction Period: Leb
NCT05149313 · Phase 3 · registry result, not featured evidence · combination
—Open-label Maintenance Period: Leb
NCT05149313 · Phase 3 · registry result, not featured evidence
—250 mg Q2W
NCT04760314 · Phase 3 · registry result, not featured evidence
—250mg Q2W
NCT04760314 · Phase 3 · registry result, not featured evidence
—250mg Q2W
NCT04760314 · Phase 3 · registry result, not featured evidence
1.6%250mg Q2W
NCT04760314 · Phase 3 · registry result, not featured evidence
0%250mg Q4W
NCT04760314 · Phase 3 · registry result, not featured evidence
—250 Q2W
NCT04760314 · Phase 3 · registry result, not featured evidence
—Q4W
NCT04760314 · Phase 3 · registry result, not featured evidence
—Q2W
NCT04760314 · Phase 3 · registry result, not featured evidence
—Q4W
NCT04760314 · Phase 3 · registry result, not featured evidence
2.4%250 mg
NCT04626297 · Phase 3 · registry result, not featured evidence
2.4%250 mg
NCT04250350 · Phase 3 · registry result, not featured evidence
—250 mg
NCT04250350 · Phase 3 · registry result, not featured evidence
—250 mg Q2W
NCT03443024 · Phase 2 · registry result, not featured evidence
5%250 mg Q4W
NCT03443024 · Phase 2 · registry result, not featured evidence
—125 mg Q4W
NCT03443024 · Phase 2 · registry result, not featured evidence
Serious AEs
2.1%250mg Q2Wa
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 54 more results
3.8%Q2W
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
1%Q2W
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
0%Escape Arm Week 24 to 48 - Mainten
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
0%Q2W
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
3.2%Q4W
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
0%Q2W
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
0%Q4W
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—250 Q2W
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—250 Q4W
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
0.7%250mg Q2W
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
4%Q2W
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
0.9%Q2W
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
0%Escape Arm Week 24 to 48 - Mainten
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
3.4%Q2W
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
0%Q4W
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
0%Q2W
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
22.2%Q4W
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—250 Q2W
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—250 Q4W
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
1.3%
NCT04250337 · Phase 3 · combination
2.7%
NCT05990725 · Phase 3 · registry result, not featured evidence
0%Q4W
NCT04392154 · Phase 3 · registry result, not featured evidence
0%Q8W
NCT04392154 · Phase 3 · registry result, not featured evidence
4.4%Q2W
NCT04392154 · Phase 3 · registry result, not featured evidence
3.5%Q4W
NCT04392154 · Phase 3 · registry result, not featured evidence
0%250 mg Q2W
NCT05372419 · Phase 3 · registry result, not featured evidence
—250 mg Q2W
NCT05372419 · Phase 3 · registry result, not featured evidence
—250 mg Q2W then 250 mg Q4W
NCT05372419 · Phase 3 · registry result, not featured evidence
0%250 mg Q2W
NCT05372419 · Phase 3 · registry result, not featured evidence
1.8%250 mg Q2W then 250 mg Q4W
NCT05372419 · Phase 3 · registry result, not featured evidence
1.2%250 mg Q2W
NCT05369403 · Phase 3 · registry result, not featured evidence
—250 mg Q2W
NCT05369403 · Phase 3 · registry result, not featured evidence
—250 mg Q2W then 250 mg Q4W
NCT05369403 · Phase 3 · registry result, not featured evidence
0%250 mg Q2W
NCT05369403 · Phase 3 · registry result, not featured evidence
2.4%250 mg Q2W then Q4W
NCT05369403 · Phase 3 · registry result, not featured evidence
—Lebrikizumab Pen
NCT06444165 · Phase 3 · registry result, not featured evidence
0%Lebrikuzimab Pen
NCT06444165 · Phase 3 · registry result, not featured evidence
1.4%Double-blind Induction Period: Leb
NCT05149313 · Phase 3 · registry result, not featured evidence · combination
5.7%Open-label Maintenance Period: Leb
NCT05149313 · Phase 3 · registry result, not featured evidence
1.4%250 mg Q2W
NCT04760314 · Phase 3 · registry result, not featured evidence
1.8%250mg Q2W
NCT04760314 · Phase 3 · registry result, not featured evidence
4.8%250mg Q2W
NCT04760314 · Phase 3 · registry result, not featured evidence
0.8%250mg Q2W
NCT04760314 · Phase 3 · registry result, not featured evidence
0%250mg Q4W
NCT04760314 · Phase 3 · registry result, not featured evidence
12.5%250 Q2W
NCT04760314 · Phase 3 · registry result, not featured evidence
0%Q4W
NCT04760314 · Phase 3 · registry result, not featured evidence
3.1%Q2W
NCT04760314 · Phase 3 · registry result, not featured evidence
2.6%Q4W
NCT04760314 · Phase 3 · registry result, not featured evidence
0.8%250 mg
NCT04626297 · Phase 3 · registry result, not featured evidence
—250 mg
NCT04250350 · Phase 3 · registry result, not featured evidence
2.4%250 mg
NCT04250350 · Phase 3 · registry result, not featured evidence
2.7%250 mg Q2W
NCT03443024 · Phase 2 · registry result, not featured evidence
0%250 mg Q4W
NCT03443024 · Phase 2 · registry result, not featured evidence
2.7%125 mg Q4W
NCT03443024 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
250mg Q2Wa
conjunctivitis 7.4% (placebo 2.8%)
dermatitis atopic 5.7% (placebo 21.3%)
nasopharyngitis 3.9% (placebo 2.8%)
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 43 more results
Q2W
conjunctivitis 4.7% (placebo 2.8%)
conjunctivitis allergic 4.7% (placebo 0.7%)
asthma 3.8% (placebo 0.7%)
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
Q2W
conjunctivitis 9.4% (placebo 2.8%)
conjunctivitis allergic 6.3% (placebo 0.7%)
dermatitis atopic 6.3% (placebo 21.3%)
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
bursitis 5.6% (placebo 0.7%)
carpal tunnel syndrome 5.6% (placebo 0%)
conjunctivitis 5.6% (placebo 2.8%)
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
Q2W
covid-19 3.2% (placebo 2.1%)
dermatitis atopic 3.2% (placebo 21.3%)
hypertension 3.2% (placebo 0.7%)
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
Q4W
covid-19 12.7% (placebo 2.1%)
nasopharyngitis 9.5% (placebo 2.8%)
dermatitis atopic 6.3% (placebo 21.3%)
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
Q2W
abscess limb 10% (placebo 0%)
chest wall abscess 10% (placebo 0%)
nasopharyngitis 10% (placebo 2.8%)
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
Q4W
covid-19 10% (placebo 2.1%)
nasopharyngitis 10% (placebo 2.8%)
oral herpes 10% (placebo 3.5%)
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
250mg Q2W
dermatitis atopic 9.2% (placebo 25.5%)
conjunctivitis 7.1% (placebo 2%)
headache 5.1% (placebo 5.4%)
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
Q2W
nasopharyngitis 8% (placebo 2%)
dermatitis atopic 4.8% (placebo 25.5%)
conjunctivitis 2.4% (placebo 2%)
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
Q2W
conjunctivitis allergic 11.1% (placebo 1.3%)
covid-19 5.6% (placebo 1.3%)
nasopharyngitis 5.6% (placebo 2%)
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
asthma 18.2% (placebo 0%)
dermatitis atopic 18.2% (placebo 25.5%)
herpes dermatitis 9.1% (placebo 1.3%)
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
Q2W
vaccination complication 6.8% (placebo 0%)
dermatitis atopic 5.1% (placebo 25.5%)
folliculitis 5.1% (placebo 2%)
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
Q4W
conjunctivitis 8.5% (placebo 2%)
conjunctivitis allergic 6.8% (placebo 1.3%)
covid-19 5.1% (placebo 1.3%)
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
Q2W
hypercholesterolaemia 18.2% (placebo 0.7%)
nasopharyngitis 18.2% (placebo 2%)
acne 9.1% (placebo 2%)
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
Q4W
arthralgia 11.1% (placebo 0.7%)
blood lactate dehydrogenase increased 11.1% (placebo 0%)
blood uric acid increased 11.1% (placebo 0%)
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
conjunctivitis 4.6% (placebo 0%)
headache 4.6% (placebo 1.3%)
hypertension 2.6% (placebo 1.3%)
NCT04250337 · Phase 3 · combination
nasopharyngitis 25.4%
conjunctivitis 17.7%
dermatitis atopic 11.5%
NCT05990725 · Phase 3 · registry result, not featured evidence
Q4W
nasopharyngitis 3.8%
acne 1.9%
attention deficit hyperactivity disorder 1.9%
NCT04392154 · Phase 3 · registry result, not featured evidence
Q8W
accessory navicular syndrome 2%
alanine aminotransferase increased 2%
arthralgia 2%
NCT04392154 · Phase 3 · registry result, not featured evidence
Q2W
covid-19 15.7%
nasopharyngitis 11.4%
dermatitis atopic 6.9%
NCT04392154 · Phase 3 · registry result, not featured evidence
Q4W
covid-19 18.4%
nasopharyngitis 9.2%
dermatitis atopic 6.4%
NCT04392154 · Phase 3 · registry result, not featured evidence
250 mg Q2W
back pain 2.2%
nasopharyngitis 2.2%
acanthosis nigricans 1.1%
NCT05372419 · Phase 3 · registry result, not featured evidence
250 mg Q2W
back pain 4.8%
blood creatine phosphokinase increased 4.8%
dermatitis atopic 4.8%
NCT05372419 · Phase 3 · registry result, not featured evidence
250 mg Q2W then 250 mg Q4W
conjunctivitis 3.6%
nasopharyngitis 3.6%
acne 1.8%
NCT05372419 · Phase 3 · registry result, not featured evidence
250 mg Q2W
dermatitis atopic 5.8%
upper respiratory tract infection 4.7%
injection site pain 3.5%
NCT05369403 · Phase 3 · registry result, not featured evidence
250 mg Q2W
concussion 5.6%
conjunctivitis 5.6%
covid-19 5.6%
NCT05369403 · Phase 3 · registry result, not featured evidence
250 mg Q2W then Q4W
joint swelling 4.9%
viral upper respiratory tract infection 4.9%
acne 2.4%
NCT05369403 · Phase 3 · registry result, not featured evidence
nasopharyngitis 12.7% (placebo 12.6%)
conjunctivitis 11.4% (placebo 1.8%)
conjunctivitis allergic 8.2% (placebo 2.7%)
NCT05149313 · Phase 3 · registry result, not featured evidence · combination
nasopharyngitis 24.5% (placebo 12.6%)
conjunctivitis 11.8% (placebo 1.8%)
conjunctivitis allergic 8.5% (placebo 2.7%)
NCT05149313 · Phase 3 · registry result, not featured evidence
250 mg Q2W
conjunctivitis allergic 18.3% (placebo 4.9%)
covid-19 18.3% (placebo 2.4%)
pyrexia 18.3% (placebo 15.9%)
NCT04760314 · Phase 3 · registry result, not featured evidence
250mg Q2W
covid-19 21.8% (placebo 2.4%)
nasopharyngitis 12.7% (placebo 2.4%)
acne 10.9% (placebo 6.1%)
NCT04760314 · Phase 3 · registry result, not featured evidence
250mg Q2W
covid-19 19% (placebo 2.4%)
herpes simplex 19% (placebo 2.4%)
nasopharyngitis 14.3% (placebo 2.4%)
NCT04760314 · Phase 3 · registry result, not featured evidence
250mg Q2W
pyrexia 20.3% (placebo 15.9%)
conjunctivitis allergic 17.1% (placebo 4.9%)
conjunctivitis 9.8% (placebo 2.4%)
NCT04760314 · Phase 3 · registry result, not featured evidence
250mg Q4W
pyrexia 18.5% (placebo 15.9%)
conjunctivitis allergic 12.3% (placebo 4.9%)
conjunctivitis 6.2% (placebo 2.4%)
NCT04760314 · Phase 3 · registry result, not featured evidence
250 Q2W
covid-19 25% (placebo 2.4%)
abdominal pain 12.5% (placebo 1.2%)
acne 12.5% (placebo 6.1%)
NCT04760314 · Phase 3 · registry result, not featured evidence
Q4W
covid-19 21.2% (placebo 2.4%)
acne 18.2% (placebo 6.1%)
headache 18.2% (placebo 11%)
NCT04760314 · Phase 3 · registry result, not featured evidence
Q2W
pyrexia 34.4% (placebo 15.9%)
conjunctivitis allergic 12.5% (placebo 4.9%)
covid-19 12.5% (placebo 2.4%)
NCT04760314 · Phase 3 · registry result, not featured evidence
Q4W
covid-19 18.4% (placebo 2.4%)
pyrexia 18.4% (placebo 15.9%)
conjunctivitis allergic 13.2% (placebo 4.9%)
NCT04760314 · Phase 3 · registry result, not featured evidence
250 mg
covid-19 5.5% (placebo 3.9%)
dermatitis atopic 4.7% (placebo 6.3%)
headache 3.1% (placebo 0.8%)
NCT04626297 · Phase 3 · registry result, not featured evidence
250 mg
dermatitis atopic 12.6%
nasopharyngitis 9.7%
covid-19 9.2%
NCT04250350 · Phase 3 · registry result, not featured evidence
250 mg Q2W
nasopharyngitis 12% (placebo 3.8%)
headache 5.3% (placebo 5.8%)
injection site pain 5.3% (placebo 1.9%)
NCT03443024 · Phase 2 · registry result, not featured evidence
250 mg Q4W
upper respiratory tract infection 11.3% (placebo 5.8%)
fatigue 5% (placebo 0%)
diarrhoea 3.8% (placebo 0%)
NCT03443024 · Phase 2 · registry result, not featured evidence
125 mg Q4W
upper respiratory tract infection 8.2% (placebo 5.8%)
nasopharyngitis 5.5% (placebo 3.8%)
bacterial vaginosis 4.3% (placebo 0%)
NCT03443024 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 35 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

lebrikizumab

IGA 0/1 40.6% (n=125) vs 18.9% (n=122) placebo @ 16wk250 mg
responder rate · % of participants
NCT04626297 · Phase 3 · registry result, not featured evidence
show 10 more results
43.1% (n=283) vs 12.7% (n=141) placebo @ 16wkQ2W
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
2.5% (n=283) vs 0.7% (n=141) placebo @ 2wkQ2W
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
10.6% (n=283) vs 0.8% (n=141) placebo @ 4wkQ2W
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
42.2% (n=246) vs 11.3% (n=123) placebo @ 16wkQ2W
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
33.2% (n=281) vs 10.8% (n=146) placebo @ 16wkQ2W
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
0.7% (n=281) vs 0% (n=146) placebo @ 2wkQ2W
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
9% (n=281) vs 1.4% (n=146) placebo @ 4wkQ2W
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
33.2% (n=281) vs 10.8% (n=146) placebo @ 16wkQ2W
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
80.6% (n=32) vs 49.8% (n=16) placebo @ 52wk250 Q4W
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
64.6% (n=32) vs 49.8% (n=16) placebo @ 52wk250 Q2W
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
EASI-75 51.2% (n=123) vs 13.4% (n=82) placebo @ 16wk250 mg Q2W
responder rate · % of participants
NCT04760314 · Phase 3 · registry result, not featured evidence
show 10 more results
58% (n=125) vs 32.7% (n=122) placebo @ 16wk250 mg
NCT04626297 · Phase 3 · registry result, not featured evidence
60.6% (n=75) vs 24.3% (n=52) placebo @ 16wk250 mg Q2W
NCT03443024 · Phase 2 · registry result, not featured evidence
47.2% (n=81) vs 13.4% (n=82) placebo @ 16wk250 mg Q4W
NCT04760314 · Phase 3 · registry result, not featured evidence
56.1% (n=80) vs 24.3% (n=52) placebo @ 16wk250 mg Q4W
NCT03443024 · Phase 2 · registry result, not featured evidence
43.3% (n=73) vs 24.3% (n=52) placebo @ 16wk125 mg Q4W
NCT03443024 · Phase 2 · registry result, not featured evidence
58.8% (n=283) vs 16.2% (n=141) placebo @ 16wkQ2W
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
52.1% (n=281) vs 18.1% (n=146) placebo @ 16wkQ2W
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
84.7% (n=53) vs 72% (n=27) placebo @ 52wk250 Q4W
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
77.4% (n=51) vs 72% (n=27) placebo @ 52wk250 Q2W
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
69.5% (n=145) vs 42.2% (n=66) placebo @ 16wk
NCT04250337 · Phase 3 · combination
EASI-90 34.3% (n=123) vs 9.8% (n=82) placebo @ 16wk250 mg Q2W
responder rate · % of participants
NCT04760314 · Phase 3 · registry result, not featured evidence
show 11 more results
39.2% (n=125) vs 18.9% (n=122) placebo @ 16wk250 mg
NCT04626297 · Phase 3 · registry result, not featured evidence
44% (n=75) vs 11.4% (n=52) placebo @ 16wk250 mg Q2W
NCT03443024 · Phase 2 · registry result, not featured evidence
28.4% (n=81) vs 9.8% (n=82) placebo @ 16wk250 mg Q4W
NCT04760314 · Phase 3 · registry result, not featured evidence
36.1% (n=80) vs 11.4% (n=52) placebo @ 16wk250 mg Q4W
NCT03443024 · Phase 2 · registry result, not featured evidence
26.1% (n=73) vs 11.4% (n=52) placebo @ 16wk125 mg Q4W
NCT03443024 · Phase 2 · registry result, not featured evidence
38.3% (n=283) vs 9% (n=141) placebo @ 16wkQ2W
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
12.4% (n=283) vs 1.6% (n=141) placebo @ 4wkQ2W
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
30.7% (n=281) vs 9.5% (n=146) placebo @ 16wkQ2W
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
6.3% (n=281) vs 1.5% (n=146) placebo @ 4wkQ2W
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
41.2% (n=145) vs 21.7% (n=66) placebo @ 16wk
NCT04250337 · Phase 3 · combination
10.7% (n=145) vs 7.2% (n=66) placebo @ 4wk
NCT04250337 · Phase 3 · combination
Pruritus NRS -60.63% (n=50) vs 4.26% (n=22) placebo @ 16wk250 mg Q2W
percent change · % of baseline
NCT03443024 · Phase 2 · registry result, not featured evidence
show 5 more results
-49.6% (n=56) vs 4.26% (n=22) placebo @ 16wk250 mg Q4W
NCT03443024 · Phase 2 · registry result, not featured evidence
-35.94% (n=55) vs 4.26% (n=22) placebo @ 16wk125 mg Q4W
NCT03443024 · Phase 2 · registry result, not featured evidence
-45.48% (n=276) vs -15.06% (n=136) placebo @ 16wkQ2W
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-36.56% (n=281) vs -9.02% (n=146) placebo @ 16wkQ2W
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-50.68% (n=139) vs -35.47% (n=63) placebo @ 16wk
NCT04250337 · Phase 3 · combination
Pruritus NRS 4-point Reduction 45.9% (n=263) vs 13% (n=130) placebo @ 16wkQ2W
responder rate · % of participants
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 15 more results
49% (n=244) vs 13.7% (n=123) placebo @ 16wkQ2W
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
2.3% (n=263) vs 0.8% (n=130) placebo @ 1wkQ2W
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
6.1% (n=263) vs 0.9% (n=130) placebo @ 2wkQ2W
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
21.5% (n=263) vs 2.3% (n=130) placebo @ 4wkQ2W
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
2.5% (n=244) vs 0.8% (n=123) placebo @ 1wkQ2W
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
6.6% (n=244) vs 0.9% (n=123) placebo @ 2wkQ2W
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
23.1% (n=244) vs 2.4% (n=123) placebo @ 4wkQ2W
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
50.6% (n=130) vs 31.9% (n=57) placebo @ 16wk
NCT04250337 · Phase 3 · combination
46.8% (n=124) vs 26.4% (n=53) placebo @ 16wk
NCT04250337 · Phase 3 · combination
23.5% (n=130) vs 9.3% (n=57) placebo @ 4wk
NCT04250337 · Phase 3 · combination
8.5% (n=130) vs 7.1% (n=57) placebo @ 2wk
NCT04250337 · Phase 3 · combination
3.8% (n=130) vs 1.8% (n=57) placebo @ 1wk
NCT04250337 · Phase 3 · combination
23.4% (n=124) vs 7.5% (n=53) placebo @ 4wk
NCT04250337 · Phase 3 · combination
8.9% (n=124) vs 7.5% (n=53) placebo @ 2wk
NCT04250337 · Phase 3 · combination
4% (n=124) vs 1.9% (n=53) placebo @ 1wk
NCT04250337 · Phase 3 · combination
EASI -64.23% (n=123) vs -25.25% (n=82) placebo @ 16wk250 mg Q2W
percent change · % of baseline
NCT04760314 · Phase 3 · registry result, not featured evidence
show 7 more results
-72.09% (n=75) vs -41.12% (n=52) placebo @ 16wk250 mg Q2W
NCT03443024 · Phase 2 · registry result, not featured evidence
-59.74% (n=81) vs -25.25% (n=82) placebo @ 16wk250 mg Q4W
NCT04760314 · Phase 3 · registry result, not featured evidence
-69.21% (n=80) vs -41.12% (n=52) placebo @ 16wk250 mg Q4W
NCT03443024 · Phase 2 · registry result, not featured evidence
-62.34% (n=73) vs -41.12% (n=52) placebo @ 16wk125 mg Q4W
NCT03443024 · Phase 2 · registry result, not featured evidence
-64.31% (n=283) vs -26.01% (n=141) placebo @ 16wkQ2W
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-61.53% (n=281) vs -27.96% (n=146) placebo @ 16wkQ2W
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-76.76% (n=145) vs -53.12% (n=66) placebo @ 16wk
NCT04250337 · Phase 3 · combination
BSA -27.55% (n=110) vs -19.34% (n=85) placebo @ 16wk250 mg
absolute change · percentage points
NCT04626297 · Phase 3 · registry result, not featured evidence
show 5 more results
-24.3% (n=59) vs -17.4% (n=24) placebo @ 16wk250 mg Q2W
NCT03443024 · Phase 2 · registry result, not featured evidence
-24.9% (n=62) vs -17.4% (n=24) placebo @ 16wk250 mg Q4W
NCT03443024 · Phase 2 · registry result, not featured evidence
-19.6% (n=59) vs -17.4% (n=24) placebo @ 16wk125 mg Q4W
NCT03443024 · Phase 2 · registry result, not featured evidence
-30.2% (n=235) vs -11.7% (n=77) placebo @ 16wkQ2W
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-30.2% (n=213) vs -14% (n=77) placebo @ 16wkQ2W
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
DLQI -8.7 vs -2.9 placebo score @ 16wkQ2W
absolute change · score
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 2 more results
-7.3 vs -2.4 placebo score @ 16wkQ2W
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-9.79 vs -6.46 placebo score @ 16wk
NCT04250337 · Phase 3 · combination
DLQI 4-Point Improvement 71.5% (n=239) vs 32.4% (n=121) placebo @ 16wkQ2W
responder rate · % of participants
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 3 more results
75.6% (n=226) vs 33.8% (n=116) placebo @ 16wkQ2W
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
65.4% (n=218) vs 32.8% (n=118) placebo @ 16wkQ2W
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
66.3% (n=215) vs 33.6% (n=115) placebo @ 16wkQ2W
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
Sleep-loss -64.69% (n=38) vs -20.24% (n=14) placebo @ 16wk250 mg Q2W
percent change · % of baseline
NCT03443024 · Phase 2 · registry result, not featured evidence
show 5 more results
-53.03% (n=33) vs -20.24% (n=14) placebo @ 16wk250 mg Q4W
NCT03443024 · Phase 2 · registry result, not featured evidence
-48.68% (n=38) vs -20.24% (n=14) placebo @ 16wk125 mg Q4W
NCT03443024 · Phase 2 · registry result, not featured evidence
-48.33% (n=269) vs -15.99% (n=132) placebo @ 16wkQ2W
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-48.37% (n=281) vs -11.29% (n=146) placebo @ 16wkQ2W
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-57.03% (n=134) vs -36.89% (n=62) placebo @ 16wk
NCT04250337 · Phase 3 · combination
Sleep-Loss -1.35 vs -0.87 placebo score @ 16wk250 mg
absolute change · score
NCT04626297 · Phase 3 · registry result, not featured evidence
show 3 more results
-1.13 vs -0.38 placebo score @ 16wkQ2W
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-1.05 vs -0.35 placebo score @ 16wkQ2W
NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-1.1 vs -0.8 placebo score @ 16wk
NCT04250337 · Phase 3 · combination
Sleep-loss 2-point Improvement 39% (n=195) vs 4.7% (n=91) placebo @ 16wkQ2W
responder rate · % of participants
NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3

+ 88 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: lebrikizumab's landscape · REGN20423's landscape